As one of the emerging markets for outsourced Clinical Drug Development, India has established its prime place as an innovative player much sought after by various Multi national companies, CR's and leading sponsors for various phases of clinical research, Clinical data management and Pharmacovigilance activities.

Over the last few years, the Indian advantage of a suitable business environment, enthusiastic human resources with superior technical capabilities and the speed of completion of trials coupled with a conducive regulatory environment has made India a proud contributor and therefore has gained recognition as a lead player in ushering in Clinical Trials Industry as a sunrise Industry. Despite the threat of recession, the year 2008 has seen India emerging as a leader among the Emerging Markets with significant increase in large Phase III trials funded by the Industry.

In view of the increasing demand for global patient enrolment shifting to Asia specially India and China, the
paucity of trained Clinical trial professionals, organizations such as CREMA have taken up this laudable task of
creating Industry oriented curriculum delivered to carefully selected students by experienced Academicians,
expert industry leaders and Management gurus.

The onus of building the right kind of capacity to meet the increasing demand for Clinical Trial professionals lies not only with organizations like CREMA but also calls for a close collaborative approach with the Industry. We at CREMA wish to place on record our deep sense of appreciation for the unstinted support, guidance and constant encouragement offered by the Pharmaceutical Industry, CRO’s and others. It gives us immense pleasure that more than 80% of our students have been recruited from campus interviews by various such organizations even before completing their course”

CREMA aims to create and nurture Clinical trial professionals who during their tenure at our various campuses learn, unlearn and relearn ultimately leading from the front in establishing India as an excellent platform for Clinical Drug Development.

Dr. R. S. Nadig
Dean & Chief Operating Officer (COO)